A Phase 1 interventional study of Metformin and Belzutifan in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn how belzutifan (MK-6482) affects the levels of metformin in a healthy person's body over time. Researchers will study levels of metformin in the blood and urine in healthy volunteers after taking metformin alone (Period 1) and metformin with belzutifan (Period 2).
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
The main inclusion criteria include, but are not limited to:
The main exclusion criteria include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1 of Period 1, a single dose of metformin will be administered.
Drug: Metformin
In Period 2, belzutifan will be administered every day for 5 consecutive days with a single dose of metformin coadministered on Day 4.
Drug: Metformin · Drug: Belzutifan
Oral Tablet
Also known as: Metformin HCl
Oral Tablet
Also known as: MK-6482
Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) for Metformin in Plasma
Blood samples will be collected to determine the AUC0-inf of metformin in plasma.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: Up to approximately 4 weeks
Number of Participants Who Discontinue Study Drug Due to an AE
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: Up to approximately 2 weeks
Area Under the Concentration Versus Time Curve from 0 to the Last Quantifiable Sample (AUC0-last) of Metformin
Plasma samples will be collected to determine the AUC0-last of metformin.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Area Under the Concentration Versus Time Curve from 0 to 24 hours (AUC0-24) of Metformin
Plasma samples will be collected to determine the AUC0-24 of metformin.
Time frame: At designated timepoints (up to approximately 24 hours post-dose metformin)
Maximum Observed Concentration (Cmax) of Metformin
Plasma samples will be collected to determine the Cmax of metformin.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Plasma Drug Concentration of Metformin at Hour 24 (C24)
Plasma samples will be collected to determine the C24 of metformin.
Time frame: 24 hours post-dose metformin
Time to Maximum Concentration (Tmax) of Metformin
Plasma samples will be collected to determine the Tmax of metformin.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Apparent Terminal Half-life (t1/2) of Metformin
Plasma samples will be collected to determine the t1/2 of metformin.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Apparent Clearance (CL/F) of Metformin
Plasma samples will be collected to determine the CL/F of metformin.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Apparent Volume of Distribution During Terminal Phase (Vz/F) of Metformin
Plasma samples will be collected to determine the Vz/F of metformin.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Total Amount of Metformin Excreted Unchanged in the Urine
Urine samples will be collected to determine the total amount of metformin excreted unchanged in the urine.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Percentage of Metformin Excreted Unchanged in Urine
Urine samples will be collected to determine the percentage of metformin excreted unchanged in urine.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Renal Clearance of Metformin
Urine samples will be collected to determine the renal clearance of metformin.
Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Aug 2025 to primary completion in Sep 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metformin · Belzutifan